GlassScriptPhysician profile
Ashok R Salvi
NPI 1740287424
$1,764.78
in general payments reported to CMS, 2019-2025
31 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $317 · 2021: $342 · 2022: $191 · 2023: $209 · 2024: $208 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.33 | 2019-2025 | Relistor |
| Vertos Medical, INC. | $184.86 | 2019-2023 | Mild Device Kit |
| Nevro Corp. | $171.09 | 2020-2024 | Senza |
| Si-Bone, INC. | $160.91 | 2019-2020 | |
| Pfizer INC. | $116.26 | 2019-2021 | |
| Boston Scientific Corporation | $93.55 | 2021-2024 | |
| Vertex Pharmaceuticals Incorporated | $72.50 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $65.00 | 2019 | |
| Biodelivery Sciences International, INC. | $54.20 | 2020-2021 | |
| Relievant Medsystems, INC. | $50.32 | 2021-2023 | Intracept |
| Amgen INC. | $44.72 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $43.85 | 2021 | |
| Allergan, INC. | $42.99 | 2020 | |
| Grt US Holding, INC. | $34.34 | 2021 | |
| Abbott Laboratories | $34.15 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $33.42 | 2019 | |
| Protega Pharmaceutials INC | $33.37 | 2023-2024 | Roxybond |
| Globus Medical, INC. | $31.57 | 2025 | Senza |
| Averitas Pharma INC. | $31.30 | 2023 | Qutenza |
| Collegium Pharmaceutical, INC. | $29.10 | 2021 | |
| Medtronic USA, INC. | $27.16 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $26.91 | 2021 | |
| Stryker Corporation | $23.70 | 2025 | Mild Device Kit |
| Valinor Pharma, LLC | $21.18 | 2025 | Movantik |
| Nalu Medical, INC. | $19.92 | 2024 | Nalu Neurostimulation System |
| Kowa Pharmaceuticals America, INC. | $18.46 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $16.03 | 2021 | |
| Medtronic, INC. | $15.62 | 2021 | |
| Daiichi Sankyo INC. | $14.06 | 2019 | |
| Almatica Pharma LLC | $11.98 | 2021 | |
| Vertical Pharmaceuticals, LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Salvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.